While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results.

J&J faces several headwinds at the start of the year, including patent expiry, talc litigation, and, now, tariffs.

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.

J&J opened Q1 2025 pharma earnings Tuesday, reporting sales of $21.9 billion and diluted earnings per share of $4.54. The medicines unit provided $13.9 billion while the medtech unit generated the ...

The looming prospect of American tariffs on pharmaceuticals would likely hit generic drugmakers the hardest, Johnson & ...

President Donald Trump’s administration pressed forward with plans to impose tariffs on semiconductor and pharmaceutical imports by initiating trade probes led by the Commerce Department. The moves, ...

Welcome to the Spruce Biosciences Investor Call [Operator Instructions]. Please note, this conference call is being recorded. I'll now turn the floor over to Samir Gharib, President and CFO of Spruce ...

Johnson & Johnson’s stock took a 2.3% dip during mid-day Wednesday trading, slipping below $150 to land around $146.56. Several analysts have responded by trimming their price targets, with Raymond ...